Fiandra Christian, Cattani Federica, Leonardi Maria Cristina, Comi Stefania, Zara Stefania, Rossi Linda, Jereczek-Fossa Barbara Alicja, Fariselli Piero, Ricardi Umberto, Heijmen Ben
Department of Oncology, University of Turin, Turin, Italy.
Unit of Medical Physics, IEO European Institute of Oncology IRCCS, Milan, Italy.
Adv Radiat Oncol. 2023 Apr 29;8(5):101228. doi: 10.1016/j.adro.2023.101228. eCollection 2023 Sep-Oct.
The objective of this work was to investigate the ability of machine learning models to use treatment plan dosimetry for prediction of clinician approval of treatment plans (no further planning needed) for left-sided whole breast radiation therapy with boost.
Investigated plans were generated to deliver a dose of 40.05 Gy to the whole breast in 15 fractions over 3 weeks, with the tumor bed simultaneously boosted to 48 Gy. In addition to the manually generated clinical plan of each of the 120 patients from a single institution, an automatically generated plan was included for each patient to enhance the number of study plans to 240. In random order, the treating clinician retrospectively scored all 240 plans as (1) approved without further planning to seek improvement or (2) further planning needed, while being blind for type of plan generation (manual or automated). In total, 2 × 5 classifiers were trained and evaluated for ability to correctly predict the clinician's plan evaluations: random forest (RF) and constrained logistic regression (LR) classifiers, each trained for 5 different sets of dosimetric plan parameters (feature sets [FS]). Importances of included features for predictions were investigated to better understand clinicians' choices.
Although all 240 plans were in principle clinically acceptable for the clinician, only for 71.5% was no further planning required. For the most extensive FS, accuracy, area under the receiver operating characteristic curve, and Cohen's κ for generated RF/LR models for prediction of approval without further planning were 87.2 ± 2.0/86.7 ± 2.2, 0.80 ± 0.03/0.86 ± 0.02, and 0.63 ± 0.05/0.69 ± 0.04, respectively. In contrast to LR, RF performance was independent of the applied FS. For both RF and LR, whole breast excluding boost PTV (PTV) was the most important structure for predictions, with importance factors of 44.6% and 43%, respectively, dose recieved by 95% volume of PTV (D) as the most important parameter in most cases.
The investigated use of machine learning to predict clinician approval of treatment plans is highly promising. Including nondosimetric parameters could further increase classifiers' performances. The tool could become useful for aiding treatment planners in generating plans with a high probability of being directly approved by the treating clinician.
本研究旨在探讨机器学习模型利用治疗计划剂量学来预测左侧全乳放疗加量治疗计划(无需进一步规划)获得临床医生批准的能力。
所研究的计划是在3周内分15次给予全乳40.05 Gy的剂量,同时肿瘤床加量至48 Gy。除了从单一机构的120例患者中手动生成的临床计划外,还为每位患者纳入了一个自动生成的计划,使研究计划数量增加到240个。治疗医生以随机顺序对所有240个计划进行回顾性评分,分为(1)无需进一步规划改进即可批准,或(2)需要进一步规划,同时对计划生成类型(手动或自动)不知情。总共训练并评估了2×5个分类器预测临床医生计划评估的能力:随机森林(RF)和约束逻辑回归(LR)分类器,每个分类器针对5组不同的剂量计划参数(特征集[FS])进行训练。研究了纳入特征对预测的重要性,以更好地理解临床医生的选择。
虽然所有240个计划原则上对临床医生来说在临床上都是可接受的,但只有71.5%的计划无需进一步规划。对于最广泛的FS,用于预测无需进一步规划即可批准的生成的RF/LR模型的准确率、受试者操作特征曲线下面积和科恩κ系数分别为87.2±2.0/86.7±2.2、0.80±0.03/0.86±0.02和0.63±0.05/0.69±0.04。与LR不同,RF的性能与所应用的FS无关。对于RF和LR,不包括加量计划靶体积(PTV)的全乳是预测中最重要的结构,重要性因子分别为44.6%和43%,在大多数情况下,95%PTV体积接受的剂量(D)是最重要的参数。
所研究的利用机器学习预测临床医生对治疗计划的批准具有很高的前景。纳入非剂量学参数可能会进一步提高分类器的性能。该工具可能有助于辅助治疗计划制定者生成很有可能直接获得治疗临床医生批准的计划。